Pulse Biosciences (NASDAQ:PLSE) Reaches New 12-Month High – What’s Next?

Pulse Biosciences, Inc (NASDAQ:PLSE) shares hit a new 52-week high during trading on Thursday . The company traded as high as $46.03 and last traded at $46.75, with a volume of 88698 shares traded. The stock had previously closed at $43.32.

Analyst Ratings Changes

A number of research analysts have recently weighed in on PLSE shares. Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Canaccord Genuity Group raised their target price on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Mizuho set a $45.00 price target on shares of Pulse Biosciences in a report on Monday. Finally, Wall Street Zen downgraded shares of Pulse Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pulse Biosciences has an average rating of “Moderate Buy” and an average target price of $41.00.

Pulse Biosciences Stock Down 0.8%

The stock has a fifty day simple moving average of $30.86 and a 200 day simple moving average of $24.67. The firm has a market capitalization of $3.08 billion, a P/E ratio of -37.75 and a beta of 1.61.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The business had revenue of $0.43 million during the quarter, compared to the consensus estimate of $0.53 million. Research analysts anticipate that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PLSE. BNP Paribas Financial Markets grew its holdings in Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after buying an additional 680 shares in the last quarter. Osterweis Capital Management Inc. purchased a new position in shares of Pulse Biosciences in the second quarter worth $28,000. Tower Research Capital LLC TRC boosted its position in shares of Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after acquiring an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after acquiring an additional 619 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Pulse Biosciences during the second quarter worth $158,000. 76.95% of the stock is currently owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.